MannKind Has Much Room for Upside in Diabetes Market: Here’s Why


MannKind Corporation (NASDAQ:MNKD) could be ready to capture an enticing amount of diabetes market share despite what the Street mostly dismissed as a third quarter stumble for its inhalable insulin Afrezza. What has H.C. Wainwright’s Oren Livnat so confident that more script growth lies ahead for the biotech firm?

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts